James, Roshan <br/><br/>
EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.  [electronic resource] 

 -  Cancer medicine  Oct 2012 
 - 114-27 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.21  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Cell Proliferation<br/>Drug Synergism<br/>ErbB Receptors--antagonists & inhibitors<br/>Humans<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinases--antagonists & inhibitors<br/>Molecular Targeted Therapy<br/>Neoplasm Transplantation<br/>Neoplasms--drug therapy<br/>STAT3 Transcription Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Sirolimus--administration & dosage<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays